Goal of the analysis:
The goal of Pipeline Attrition Rate and Risk Mitigation analysis is to assess the rate at which drug candidates fail during the various phases of the development pipeline (Preclinical, Phase I, Phase II, Phase III). By evaluating these attrition rates, a company can identify where the highest risks are in their R&D process and implement strategies to reduce the likelihood of failure, improve efficiency, and optimize resource allocation.
Data required:
- Number of drug candidates entering each phase (Preclinical, Phase I, Phase II, Phase III).
- Number of drug candidates failing to advance to the next phase.
- Reasons for failure (e.g., safety issues, lack of efficacy, regulatory hurdles).
- Industry benchmark attrition rates for each phase.
- Historical attrition rates for the company’s pipeline.
- Resource allocation per phase (time, personnel, and budget).
- Risk mitigation strategies already in place (e.g., adaptive trial designs, biomarker use, external partnerships).
Detailed step-by-step instruction on how to conduct the analysis:
- Data Collection:
- Collect historical data on the number of drug candidates entering and exiting each phase of development (Preclinical, Phase I, Phase II, Phase III).
- Identify key reasons for drug candidate failure at each phase. These reasons could include safety concerns, lack of efficacy, manufacturing challenges, or regulatory barriers.
- Calculate Attrition Rate for Each Phase:
- Use the following formula to calculate the attrition rate for each phase:
Attrition Rate (Phase X) = (Number of Candidates Failing in Phase X / Total Number of Candidates Entering Phase X) * 100 - This will yield the percentage of candidates that fail to progress from one phase to the next.
- Use the following formula to calculate the attrition rate for each phase:
- Compare with Industry Benchmarks:
- Compare the company’s attrition rates with industry averages. Typical industry attrition rates are:
- Preclinical: ~90% failure rate
- Phase I: ~40% failure rate
- Phase II: ~70% failure rate
- Phase III: ~50% failure rate
- If the company’s attrition rates are significantly higher than industry benchmarks, it may indicate inefficiencies in drug development, poor candidate selection, or issues in trial design.
- Compare the company’s attrition rates with industry averages. Typical industry attrition rates are:
- Analyze Risk Concentration:
- Identify phases where the company experiences the highest attrition. For example, if a large percentage of drugs fail in Phase II, it could indicate poor target selection or trial design issues. Conversely, high attrition in Preclinical could suggest inefficiencies in candidate identification or early-stage validation.
- Examine which therapeutic areas show the highest attrition rates. Some areas, like oncology, tend to have higher attrition due to complex biological targets and stringent regulatory requirements.
- Risk Mitigation Strategies:
- Assess current risk mitigation strategies in place to reduce attrition, such as:
- Use of biomarkers: Incorporating biomarkers can improve patient selection and increase the likelihood of trial success.
- Adaptive trial designs: These allow modifications to the trial based on interim results, helping to reduce the risk of failure in later phases.
- Preclinical validation: Ensure thorough preclinical validation, including mechanistic studies and toxicity assessments, to improve the chances of success in clinical trials.
- Partnerships with CROs (Contract Research Organizations): Partnering with external experts can reduce trial failures by improving study design, execution, and data management.
- Assess current risk mitigation strategies in place to reduce attrition, such as:
- Optimize Resource Allocation:
- Evaluate how resources (e.g., budget, time, personnel) are allocated across phases. If a phase with high attrition is under-resourced, increasing investment in that phase may reduce failure rates.
- Ensure that resources are not overly concentrated on a single high-risk candidate or therapeutic area, which could increase overall portfolio risk.
Format of the output of analysis:
The output will typically be a narrative summary of attrition rates and associated risks, along with proposed mitigation strategies. For example:
- Preclinical Attrition Rate: 85% of the company’s drug candidates fail to advance from preclinical testing to Phase I. This is slightly better than the industry average of 90%, suggesting strong early-stage validation. However, further refinement in target identification could reduce this rate further.
- Phase II Attrition Rate: The company’s Phase II attrition rate is 75%, which exceeds the industry benchmark of 70%. This higher-than-average rate suggests challenges in efficacy or patient recruitment. Implementing biomarkers to refine patient selection and adaptive trial designs could help mitigate this risk.
- Risk Concentration in Oncology: The oncology portfolio shows an attrition rate of 80% in Phase II, significantly higher than other therapeutic areas. This may reflect the inherent difficulty of developing cancer therapies, but further scrutiny is needed to ensure that the company is not over-investing in high-risk oncology candidates.
How to interpret results:
- High Attrition Rates: If attrition rates are high, particularly in critical phases like Phase II or III, the company’s R&D strategy may require adjustments. High failure rates could indicate that drug candidates are being advanced too quickly without sufficient validation or that the clinical trial designs are suboptimal.
- Low Attrition Rates: While low attrition rates may seem positive, they could indicate that the company is being too conservative in its candidate selection, potentially missing out on high-reward opportunities.
- Therapeutic Area Variability: High attrition rates in specific therapeutic areas (e.g., oncology, neurology) may reflect inherent risks in those fields. Companies may need to weigh the risks of pursuing high-attrition areas against the potential rewards (e.g., oncology drugs typically have high market potential if successful).
Steps a company can take to improve on this measure:
- Strengthen Preclinical Validation: Improve preclinical testing to better identify viable drug candidates before advancing them into clinical trials. Techniques like predictive modeling, mechanistic studies, and toxicity screening can help filter out candidates likely to fail in later phases.
- Incorporate Adaptive Trial Designs: Using adaptive designs allows trials to be modified based on interim results, such as adjusting doses or expanding the patient population. This can reduce the likelihood of failure in later phases.
- Use Biomarkers for Patient Selection: Incorporating biomarkers to select patients who are more likely to respond to treatment can improve success rates in clinical trials, particularly in Phase II.
- Increase Collaboration with External Partners: Partnering with academic institutions, biotech firms, or contract research organizations (CROs) can help de-risk drug development by bringing in additional expertise, reducing the company’s exposure to clinical failures.
- Reallocate Resources to High-Potential Candidates: Focus resources (budget, personnel, time) on candidates with the highest potential for success, based on early-phase data and preclinical validation. Conversely, deprioritize or abandon candidates with high risk and low likelihood of success.
- Diversify the Pipeline: Reducing concentration in high-risk therapeutic areas or developing a more balanced pipeline across several therapeutic areas can mitigate the risk of large-scale failures.
Request the PDF Download of How to Analyze a Pharmaceutical Company
